Alderley Park, 29 July 2022 – Blueberry Therapeutics are pleased to announce that recruitment into our Phase 2b European trial of BB2603 for fungal nail infection is now complete.
This trial (BBTAF202) assesses the efficacy and safety of different doses of BB2603, a new topical anti-fungal formulation, in patients with fungal nail infection (onychomycosis). Data from the primary endpoint (an early response assessment at 16 weeks) are expected in Q1 2023, with final results to follow for the 52-week endpoints.
For more information about Blueberry Therapeutics please contact:
Dr Emma Leigh, Director of Communications
info@blueberrytherapeutics.com
About Blueberry Therapeutics
Blueberry Therapeutics is a pharmaceutical company focused on the discovery, development and commercialisation of high value medicines for the treatment of common dermatological conditions that will positively impact on treatment outcomes and improve patient quality of life.
Blueberry applies innovative technologies to improve the delivery of existing drugs through the skin and nail. This enables better efficacy, safety and patient compliance while reducing drug dosage and cost of goods. The Company has a de-risked portfolio of best-in-class [advanced stage] clinical and preclinical assets addressing high value and poorly served indications in dermatology, including onychomycosis (fungal nail infection), tinea pedis (athletes’ foot) and atopic dermatitis (eczema).